S. Cho

发表

MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis In Vivo

S. Barry, J. Kendrew, V. Bedian, 2012, Molecular Cancer Therapeutics.

Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics.

Fengying Huang, R. Hollingsworth, Herren Wu, 2016, Journal of Controlled Release.

Hydrolytically Stable Site-Specific Conjugation at the N-Terminus of an Engineered Antibody.

Herren Wu, P. Thompson, Changshou Gao, 2015, Bioconjugate chemistry.

Generation of a functional humanized Delta-like ligand 4 transgenic mouse model

Johan Johansson, C. Morehouse, Nicholas Holoweckyj, 2017, Transgenic Research.

Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody–Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide

D. Petrylak, M. Fleming, R. Cathomas, 2021, Clinical Cancer Research.

Delta-like ligand 4-notch blockade and tumor radiation response.

A. Harris, R. Muschel, J. Im, 2011, Journal of the National Cancer Institute.

Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer

N. Bander, E. Corey, R. Tammali, 2018, Molecular Cancer Therapeutics.

MEDI3726, a prostate-specific membrane antigen (PSMA)-targeted antibody-drug conjugate (ADC) in mCRPC after failure of abiraterone or enzalutamide.

M. Fleming, D. Petrylak, R. Cathomas, 2020 .

Dll4-Notch Signalling Blockade Synergizes Combined Ultrasound-Stimulated Microbubble and Radiation Therapy in Human Colon Cancer Xenografts

G. Czarnota, J. Nofiele, A. Giles, 2014, PloS one.

MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis In Vivo

S. Barry, J. Kendrew, V. Bedian, 2012, Molecular Cancer Therapeutics.